Profession Notes

Partnership to Test Vaccine Candidates Yerkes Regional Primate Research Center Mary R. Galinski A new partnership forming between Emory University's Vaccine Research Center in Atlanta and the Malaria Vaccine Initiative (MVI) in Rockville, Md., will enable the testing of several vaccine candidates developed by institutions worldwide. MVI, which is part of the Program for Appropriate Technology in Seattle that conducts health programs globally, will sponsor the effort. Mary R. Galinski, of the

Written byKate Devine
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Yerkes Regional Primate Research Center Mary R. Galinski A new partnership forming between Emory University's Vaccine Research Center in Atlanta and the Malaria Vaccine Initiative (MVI) in Rockville, Md., will enable the testing of several vaccine candidates developed by institutions worldwide. MVI, which is part of the Program for Appropriate Technology in Seattle that conducts health programs globally, will sponsor the effort. Mary R. Galinski, of the division of infectious diseases at Emory's Department of Medicine and an affiliate scientist at the Yerkes Regional Primate Research Center where the Vaccine Research Center is located, will lead the open-ended, multiyear effort. According to Galinski, the main focus will be on the two most predominant of the four human malaria species, Plasmodium falciparum and Plasmodium vivax, "Together these two species cause most of the annual estimated 300-500 million cases of malaria. Moreover, these two species diverged many years ago and a vaccine ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies